For decades, the luxury skincare industry operated as a high-margin consumer category—a commoditized market built on aesthetic masking. That era has concluded. We are currently witnessing a decisive migration of R&D capital into a new domain: Cellular Longevity. This is not a shift in marketing; it is a fundamental re-engineering of the industry's value chain, moving from cosmetic maintenance to high-barrier biological intervention. The market has bifurcated. On one side,

Switzerland hasn't just become a family office fortress; it has become the global headquarters for the "Biological Balance Sheet." The headlines suggest that Swiss banking secrecy ended in 2018. The reality? Capital is flooding in faster than ever. But a more profound shift is occurring beneath the surface. Families are no longer establishing $4B+ single-family offices (SFOs) merely to manage portfolios. They are anchoring themselves in Switzerland to manage the most criti

When L Catterton, the private equity fund backed by LVMH and Groupe Arnault, invested up to US$5 million in WTHN, the New York brand modernizing Traditional Chinese Medicine (TCM), they were not merely diversifying a portfolio. They were signaling the next era of luxury: East-meets-West longevity.

L Catterton, the private equity fund backed by LVMH and Groupe Arnault, has invested up to US$5 million in WTHN, the New York-based brand that modernises Traditional Chinese Medicine (TCM) through a clean, design-led luxury model.

In East Asia, longevity is not merely a sector—it is a strategic ethos. From the timeless streets of Tokyo, to the innovation corridors of Seoul, across Beijing’s vast horizons, through the vibrant pulse of Hong Kong, and the refined neighborhoods of Taipei, wellness is architected into daily life, technology, and urban infrastructure. The region offers a canvas where scale, sophistication, and exclusivity converge, producing opportunities as investable as they are visionary.